Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextromethorphan-Bupropion Neuroimaging Study in MDD
NCT07523048Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dextromethorphan + bupropion in major depressive disorder (MDD). Started Nov 2025; status: recruiting.
02
Drugs
dextromethorphan + bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07523048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523048.